Table 2 Studies of children with bronchiolitis and post-bronchiolitis, and acute asthma treated with montelukast
From: Update on leukotriene receptor antagonists in preschool children wheezing disorders
| Â | Author | Pros | Cons |
|---|---|---|---|
| Â | Â | Â | No difference: |
| Â | Â | Â | - in length of stay |
| Â | Amirav[47] | Â | - in clinical severity score |
| Â | Â | Â | - in cytokine levels in nasal lavage fluid |
| Â | Bisgaard[48] | Â | No differences in percentage symptom-free days |
| Â | Â | Â | No differences: |
Bronchiolitis and post bronchiolitis | Proesmans[49] | Â | - of symptoms and disease-free days and nights |
|  |  |  | - of n° of exacerbations |
|  |  |  | - of n° of unscheduled visits and need of inhaled steroids |
| Â | Â | Higher percentage of symptom-free days and nights | Â |
| Â | Bisgaard[50] | Reduced daytime cough | Â |
| Â | Â | Decreased exacerbations versus placebo | Â |
| Â | Kim[51] | Reduced serum eosinophil-derived neurotoxin levels compared with initial levels | Â |
|  | Decreased cumulative recurrent wheezing episodes at 12 months versus placebo |  | |
| Â | Harmanci[52] | Reduced oral steroids need | Â |
Acute asthma | Â | Decreased lung index scores and respiratory rate versus placebo | Hospitalization rates not significantly different |
|  | Robertson[33] | Reduced healthcare resource use, symptoms, time-off school/parent work | No effect on hospitalization rate, symptoms duration, β2 or steroids use |
| Â | Bacharier[40] | Â | No difference in symptom free-days, oral steroid, healthcare resource use |